Literature DB >> 28256714

Recent advances in the understanding of severe cutaneous adverse reactions.

N R Adler1,2, A K Aung1,2, E N Ergen3, J Trubiano4,5, M S Y Goh2, E J Phillips6,7.   

Abstract

Severe cutaneous adverse reactions (SCARs) encompass a heterogeneous group of delayed hypersensitivity reactions, which are most frequently caused by drugs. Our understanding of several aspects of SCAR syndromes has evolved considerably over the last decade. This review explores evolving knowledge of the immunopathogenic mechanisms, pharmacogenomic associations, in vivo and ex vivo diagnostics for causality assessment, and medication cross-reactivity data related to SCAR syndromes. Given the rarity and severity of these diseases, multidisciplinary collaboration through large international, national and/or multicentre networks to collect prospective data on patients with SCAR syndromes should be prioritized. This will further enhance a systematized framework for translating epidemiological, clinical and immunopathogenetic advances into preventive efforts and improved outcomes for patients.
© 2017 British Association of Dermatologists.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28256714      PMCID: PMC5582023          DOI: 10.1111/bjd.15423

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  173 in total

1.  Imipenem in patients with immediate hypersensitivity to penicillins.

Authors:  Antonino Romano; Marinella Viola; Rosa-Maria Guéant-Rodriguez; Francesco Gaeta; Rosa Pettinato; Jean-Louis Guéant
Journal:  N Engl J Med       Date:  2006-06-29       Impact factor: 91.245

2.  HLA-B*58:01 is strongly associated with allopurinol-induced severe cutaneous adverse reactions in Han Chinese patients: a multicentre retrospective case-control clinical study.

Authors:  L Cheng; Y Xiong; C Z Qin; W Zhang; X P Chen; J Li; H H Zhou
Journal:  Br J Dermatol       Date:  2015-06-22       Impact factor: 9.302

Review 3.  Hypersensitivity to aromatic anticonvulsants: in vivo and in vitro cross-reactivity studies.

Authors:  Antonino Romano; Rosa Pettinato; Maria Andriolo; Marinella Viola; Rosa-Maria Guéant-Rodriguez; Rocco Luigi Valluzzi; Corrado Romano; Maurizio Elia; Maria Teresa Ventura; Jean-Louis Guéant
Journal:  Curr Pharm Des       Date:  2006       Impact factor: 3.116

Review 4.  Fever, rash, and systemic symptoms: understanding the role of virus and HLA in severe cutaneous drug allergy.

Authors:  Rebecca Pavlos; Simon Mallal; David Ostrov; Yuri Pompeu; Elizabeth Phillips
Journal:  J Allergy Clin Immunol Pract       Date:  2014 Jan-Feb

5.  2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis.

Authors:  Dinesh Khanna; Puja P Khanna; John D Fitzgerald; Manjit K Singh; Sangmee Bae; Tuhina Neogi; Michael H Pillinger; Joan Merill; Susan Lee; Shraddha Prakash; Marian Kaldas; Maneesh Gogia; Fernando Perez-Ruiz; Will Taylor; Frédéric Lioté; Hyon Choi; Jasvinder A Singh; Nicola Dalbeth; Sanford Kaplan; Vandana Niyyar; Danielle Jones; Steven A Yarows; Blake Roessler; Gail Kerr; Charles King; Gerald Levy; Daniel E Furst; N Lawrence Edwards; Brian Mandell; H Ralph Schumacher; Mark Robbins; Neil Wenger; Robert Terkeltaub
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-10       Impact factor: 4.794

6.  Association analysis of drug metabolizing enzyme gene polymorphisms in HIV-positive patients with co-trimoxazole hypersensitivity.

Authors:  M Pirmohamed; A Alfirevic; J Vilar; A Stalford; E G Wilkins; E Sim; B K Park
Journal:  Pharmacogenetics       Date:  2000-11

7.  Genetic variations in HLA-B region and hypersensitivity reactions to abacavir.

Authors:  Seth Hetherington; Arlene R Hughes; Michael Mosteller; Denise Shortino; Katherine L Baker; William Spreen; Eric Lai; Kirstie Davies; Abigail Handley; David J Dow; Mary E Fling; Michael Stocum; Clive Bowman; Linda M Thurmond; Allen D Roses
Journal:  Lancet       Date:  2002-03-30       Impact factor: 79.321

8.  Positive and negative associations of HLA class I alleles with allopurinol-induced SCARs in Koreans.

Authors:  Hye-Ryun Kang; Young Koo Jee; Yon-Soo Kim; Chang Hwa Lee; Jae-Woo Jung; Sae Hoon Kim; Heung-Woo Park; Yoon-Seok Chang; In-Jin Jang; Sang-Heon Cho; Kyung-Up Min; Sang-Heon Kim; Kyung Wha Lee
Journal:  Pharmacogenet Genomics       Date:  2011-05       Impact factor: 2.089

9.  HLA-B*58:01 allele is associated with augmented risk for both mild and severe cutaneous adverse reactions induced by allopurinol in Han Chinese.

Authors:  Zhi-hao Cao; Zhi-yun Wei; Qin-yuan Zhu; Jun-yu Zhang; Lun Yang; Sheng-ying Qin; Li-yan Shao; Yi-ting Zhang; Jie-kun Xuan; Qiao-li Li; Jin-Hua Xu; Feng Xu; Li Ma; Hui-yuan Huang; Qing-he Xing; Xiao-qun Luo
Journal:  Pharmacogenomics       Date:  2012-07       Impact factor: 2.533

Review 10.  Antiepileptic drug-induced hypersensitivity syndrome reactions.

Authors:  Norberto Krivoy; Masud Taer; Manuela G Neuman
Journal:  Curr Drug Saf       Date:  2006-08
View more
  4 in total

1.  The Immunogenetics of Cutaneous Drug Reactions.

Authors:  Neda Khalili
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

2.  Sex Differences in the Risk of Cutaneous Adverse Drug Reactions Induced by Antiseizure Medications: A Systematic Review and Meta-analysis.

Authors:  Israa Alfares; Muhammad Shahid Javaid; Zhibin Chen; Alison Anderson; Ana Antonic-Baker; Patrick Kwan
Journal:  CNS Drugs       Date:  2021-02-12       Impact factor: 5.749

3.  Cross With Caution: Antibiotic Cross-Reactivity and Co-Reactivity Patterns in Severe Cutaneous Adverse Reactions.

Authors:  Grace Thompson; Andrew McLean-Tooke; Michaela Lucas
Journal:  Front Immunol       Date:  2021-02-25       Impact factor: 7.561

4.  A case of cefditoren-induced acute generalized exanthematous pustulosis during COVID-19 pandemics. Severe cutaneous adverse reactions are an issue.

Authors:  I Torres-Navarro; C Abril-Pérez; J Roca-Ginés; J Sánchez-Arráez; R Botella-Estrada
Journal:  J Eur Acad Dermatol Venereol       Date:  2020-07-02       Impact factor: 9.228

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.